Viking Therapeutics, Inc.

Welcome to the Viking Therapeutics First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press the star key followed by 1 on your touch-tone phone. If anyone has difficulty hearing the conference, please press star 0 for operator assistance. As a reminder, this conference call is being recorded today. April 26, 2023. I would now like to turn the conference over to Vikings Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.

Hello, and thank you all for participating in today's call. Joining me today is Brian Lynn, Vikings President and CEO, and Greg Zanti, Vikings CFO. Before we begin, I'd like to caution that comments made during this conference call today, April 26, 2023 will contain forward-looking statements under the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Vikings' expectations regarding its development activities, timelines, and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. I'll now turn the call over to Brian Land for his initial comments.

Thanks, Stephanie, and good afternoon to everyone dialed in by phone or listening on the webcast. Today, we'll review our financial results for the first quarter of 2023. and provide an update on recent progress with our clinical programs and operations. The first quarter of 2023 was an exciting time at Viking, with important progress announced across multiple clinical programs. With respect to VK2809, our lead thyroid hormone receptor beta agonist for the treatment of NASH and fibrosis, early in the quarter we announced completion of enrollment in our Phase IIb voyage trial, and we expect to announce top-line data from the primary endpoint in this study in the second quarter of 2023. With respect to our newest clinical program, the dual GLP-1 and GIP receptor agonists, VK2735, for the potential treatment of metabolic disorders, last month we announced data from our first clinical study of this compound, a Phase I single ascending dose and multiple ascending dose study in healthy volunteers. As we'll discuss in a few minutes, the results were encouraging, with mean weight loss of up to 18 pounds observed following 28 days of treatment. We plan to initiate a Phase II study of VK2735 in patients with obesity in mid-2023. In addition, we announced the initiation of a new clinical study to evaluate a novel oral formulation of this compound. With respect to our third ongoing clinical program, the novel thyroid hormone beta receptor agonist VK0214, our Phase Ib trial evaluating this compound for the treatment of X-linked adrenoleukodystrophy continues to enroll, and we expect to report the results from this study in the second half of the year. Late in the quarter, we also completed the successful public offering of common stock, raising gross proceeds of approximately $288 million that we plan to use for the continued advancement of each of our programs through key clinical milestones. I'll provide further details on our operations and development activities after we review our first quarter 2023 financial results. For that, I'll turn the call over to Greg Zante, Vikings Chief Financial Officer.